Delving into the Latest Updates on HAO1 inhibitor(Haisco) with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target

GOX

Mechanism

GOX inhibitors(Hydroxyacid oxidase 1 inhibitors)

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseUrogenital Diseases+ [1]

Active Indication

Kidney CalculiPrimary Hyperoxaluria Type 1

Inactive Indication-

Originator Organization

Tibet Haisco Pharmaceutical Co. Ltd.

Active Organization

Tibet Haisco Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Glycolate oxidase (HAO1) catalyses the synthesis of glyoxylate, a common metabolic intermediate that causes renal failure if accumulated. HAO1 inhibition is an emerging treatment for primary hyperoxaluria, a rare disorder of glyoxylate metabolism. Here we report the first cell-based measurement of inhibitor uptake and engagement with HAO1, by adapting the cellular thermal shift assay (CETSA) based on Nano luciferase complementation and luminescence readout. By profiling the interaction between HAO1 and four well-characterised inhibitors in intact and lysed HEK293T cells, we showed that our CETSA method differentiates between low-permeability/high-engagement and high-permeability/low-engagement ligands and is able to rank HAO1 inhibitors in line with both recombinant protein methods and previously reported indirect cellular assays. Our methodology addresses the unmet need for a robust, sensitive, and scalable cellular assay to guide HAO1 inhibitor development and, in broader terms, can be rapidly adapted for other targets to simultaneously monitor compound affinity and cellular permeability.

100 Deals associated with HAO1 inhibitor(Haisco)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Calculi	Preclinical	CN	Tibet Haisco Pharmaceutical Co. Ltd.	31 May 2024
Primary Hyperoxaluria Type 1	Preclinical	CN	Tibet Haisco Pharmaceutical Co. Ltd.	31 May 2024